tbuckley/cabot-search huggingface dataset:
GOUT: A CLINICAL STUDY OF ONE HUNDRED AND SIXTEEN CASES
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Syllabus of Lectures on Human Embryology. An Introduction to the Study of Obstetrics and Gynecology for Medical Students and Practitioners.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Toxicity of indomethacin. Report of a case of acute pancreatitis
Authors: M. Guerra
Journal: JAMA (1967)

SINCE its recent introduction, the nonsteroidal chemical called indomethacin (1-[<i>p</i>-chlorobenzoyl]-5-methoxy-2-methylindole-3-acetic acid) has been used extensively as a new "antirheumatic"<sup>1</sup>drug that has anti-inflammatory,<sup>2</sup>analgesic, and antipyretic<sup>3</sup>activity. The side effects have been described by various authors. These were usually limited to the central nervous system, with symptoms of headache, vertigo, light-headedness, and disturbed sensorium; and to the gastrointestinal system, with the symptoms of cramping, epigastric pain, and peptic ulceration.<sup>4</sup> We found no mention of pancreatic involvement recorded in the literature. In the case being reported, the patient's condition was not associated with biliary tract disease, alcoholism, or any of the other conditions usually considered important in the cause of pancreatitis. We believe this case gives evidence that indomethacin does have a direct and toxic effect on the pancreas. <h3>Report of a Case</h3> A 69-year-old Negro man was admitted to the hospital on Aug 21,
Primary therapy of Waldenstrom’s macroglobulinemia with bortezomib, dexamethasone and rituximab: Results of WMCTG clinical trial 05–180
Authors: S. P. Treon, L. Ioakimidis, J. D. Soumerai, C. J. Patterson, Z. R. Hunter, A. Feiner, J. Mattern, A. Birner, A. Boral, I. M. Ghobrial
Journal: Journal of Clinical Oncology (2008)

8519 Rituximab and bortezomib are each active in Waldenstrom’s macroglobulinemia (WM) producing major response rates of 40- 50%, but no complete responses (CR). Synergistic activity for these agents together, and with steroids has been shown in preclinical studies. As such, we examined the activity of combined bortezomib, dexamethasone, and rituximab in patients with WM. Intended therapy consisted of IV bortezomib at 1.3 mg/m2 and IV dexamethasone 40 mg on days 1, 4, 8, and 11, and Rituximab at 375 mg/m2 on day 11 which constituted one cycle of therapy. Patients received 4 consecutive cycles, followed by a 3 month pause, and then 4 more cycles, each given 3 months apart. Twenty-three patients were enrolled and are all evaluable for toxicity and response. Following a median of 7 (range 3–8) cycles of therapy, median serum IgM levels declined from 4,830 (range 458–9,550 mg/dL) to 1,150 (range 18–4,930 mg/dL) (p=7.7x10- 6), and median hematocrit rose from 29.8 (range 19.5–50.5%) to 38.2 (range 28–47.8%) (p=8.8 x 10-5). The major (≥50% decrease in IgM) and overall response rates were 78% and 96% with 4 CR/nCR; 14 PR, and 4 minor (≥25% decrease in IgM) responses. Responses were prompt, and occurred at a median of 1.1 (range 0.3–11.7) months. With a median follow-up of 14.7 (range 3.3–25.2) months, 20/23 patients remain free of disease progression. Peripheral neuropathy was the most common toxicity and occurred in 16 patients (grade 2, n=9; grade 3, n=7), and resolved ≤ grade 1 in 12/16 patients at a median of 6.3 months. Other grade ≥ 3 toxicities attributed to protocol therapy included arrhythmia (n=1); hypotension (n=1); neutropenia (n=1); pneumonia (n=1), sepsis (n=1) and thrombocytopenia (n=2). Four of the first 7 patients on study developed herpes zoster while on treatment, resulting in the implementation of valcyclovir prophylaxis with good effect. The results of this study demonstrate that BDR produces high response rates including complete remissions in patients with WM. Reversible peripheral neuropathy is the most common toxicity observed on the twice a week schedule of bortezomib employed in this study. Ongoing efforts utilizing once a week bortezomib (at 1.6 mg/m2) in combination therapy are being explored at our institution in patients with WM. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Millennium Millennium Millennium Millennium
Plenary oral presentations
Authors: J Bohr, C Tysk, S Eriksson, M Menegatti, D Vaira, M Miglioli, J Holton, P Mule, G Biasco, M Lombardi, R Conte
Journal: Gut (1994)

During the years 199211993, data on patients with collagenous colitis have been collected from most parts of Sweden.By the end of 1993, data on 11 3 patients were available.Epidemiological figures, associated diseases of inflammatory or autoimmune origin, and experience of medical treatment based on a retrospective analysis are presented.Results.Distribution of patients: 96 women (85%), 17 men (15%).Mean age at diagnosis: 54 years (18-85 years).Prevalence in the Orebro area on Dec 31, 1993: 16.4/105 inhabitants (95% Cl; 10.4-22.4/105).Associated diseases: Rheumatoid arthritis, 15 pat (13%); Thyroid disor- ders, 14(12%); Celiac disease 6(5%); among other diseases of inflammatory or autoimmune origin, diabetes mellitus, bronchial asthma, IBD, Sjogrens dis- ease and psoriatic disease were represented.Treatment.' Out of 74 patients treated with sulphasalazine, 37 benefitted from this treatment, 9 had no effect, and 28 patients were intolerent.All 9 patients treated with some kind of penicillin responded. 18of 28 patients treated with metronidazole, and 6 of 9 treated with erythromycine responded.Prednisolone had effect in 24 out of 27 patients.Conclusions.Distribution of sex and age are in agreement with earlier re- ports.We estimate the prevalence to 16.4/105 inhabitants.Our data confirm that collagenous colitis is associated with diseases of inflammatory or autoimmune origin.Retrospective evaluation of different medical treatments, shows that treat- ment with sulphasalazine should have first priority, though a considerable number of patients are intolerant.Antibiotics often have beneficial but no sustained effect.Prednisolone is effective, and can be used for short term treatment.
Human Rabies—Texas, 1990
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fungal? Fungous?
Authors: R. J. Dancey
Journal: JAMA (1966)

<h3>To the Editor:—</h3> I am somehow disturbed whenever I see<i>fungous</i>used to mean caused by a fungus, as in "The Biology of Fungous Infections of the Feet" (<b>197</b>:1017, 1966). I admit that this usage does occur in medical literature, and that Webster gives "caused by a fungus" as its second definition of the word. Some further justification might be argued on the ground that "full of" is included among the various meanings of the English suffix<i>-ous</i>. Thus,<i>fungous disease</i>is full of fungi. But I believe the usual meaning is still "of the nature of or resembling a fungus." This is the only definition given in the 1965 edition of<i>Dorland's Medical Dictionary</i>. I view the two meanings as separate and distinct, but perhaps the authors of the article cited<i>do</i>mean that infection and disease caused by a fungus are "like a fungus." What alternatives have
Court backs states on abortion
Authors: C. Marwick
Journal: JAMA (1989)

READERS WILL see a new heading in this week's Medical News &amp; Perspectives section—From the Congressional Office of Technology Assessment. This is the first report of its kind in<i>JAMA</i>from this small but influential office, some functions of which are explained in the editorial on page 550. Also in this week's section, under a different heading (From the Assistant Secretary for Health), is an outline of health objectives for the closing years of this century.<i>JAMA</i>has carried these secretarial reports for more than a year and a half, but this is the first from the new assistant secretary, James O. Mason, MD, DrPH (<i>JAMA</i>. 1989;261: 3367).—by
Alliance A091102: Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.
Authors: Mark Andrew Dickson, Michelle R. Mahoney, William D. Tap, Sandra P. D'Angelo, Mary Louise Keohan, Brian Andrew Van Tine, Mark Agulnik, Laura E. Horvath, Gary K. Schwartz
Journal: Journal of Clinical Oncology (2014)

10527 Background: About 13,000 cases of soft tissue and bone sarcoma are diagnosed annually in the US. Despite surgery many patients (pts) develop recurrent disease. Response rates (RR) to chemotherapy are low; new agents are needed. In gene array studies Aurora Kinase A (AURKA) is commonly overexpressed. Inhibition of AURKA by shRNA or by a specific AURKA inhibitor blocks in vitro proliferation of multiple sarcoma subtypes. MLN8237 (alisertib) is a novel, oral, ATP-competitive, selective small-molecule inhibitor of AURKA. Methods: This multi-center phase II study of alisertib in pts with advanced/metastatic sarcoma was conducted through the Alliance for Clinical Trials in Oncology (A091102). Adequate performance status, organ function, and measurable disease (RECIST v1.1) were required. Pts enrolled into histology-defined cohorts: 1) liposarcoma (LPS), 2) leiomyosarcoma (LMS), 3) undifferentiated sarcoma (US), 4) malignant peripheral nerve sheath tumor (MPNST), or 5) other. Alisertib 50mg PO BID d1-d7 was given every 21 days until progressive disease (PD) or unacceptable toxicity. The primary endpoint was confirmed RR in each of 5 cohorts. Progression-free survival (PFS) was a secondary endpoint. 1 confirmed response in the first 9 pts expanded enrollment in a cohort to 24 using a Simon 2-stage design. Results: 72 pts were enrolled at 24 sites (12 LPS, 10 LMS, 13 US, 10 MPNST, and 27 Other). Median age was 55 (range 20-84); 54% were male; 58/38/4% were ECOG PS 0/1/2. 1 confirmed PR in the Other cohort (angiosarcoma) expanded to 2nd stage accrual. The histology-specific cohorts ceased at the 1st stage. Overall, 76% have PD; 25% have died, with median follow-up of 4.4 months (0.4-11.9). 12-week PFS was 73% (LPS), 44% (LMS), 23% (US), 57% (MPNST), and 39% (Other). Common grade 3-4 adverse events included (%): mucositis (13), anemia (14), leukopenia (22), and neutropenia (40). Conclusions: Alisertib was well-tolerated in this study of multiple sarcoma histologic subtypes. Rare responses, yet prolonged stable disease, were observed. Although failing to meet the primary RR endpoint, PFS was promising. Alisertib warrants further study in sarcoma. Clinicaltrials.gov:NCT01653028. Funded by the Alliance for Clinical Trials in Oncology Clinical trial information: NCT01653028.
Gonorrhea in preschool- and school-aged children. Report of the prepubertal gonorrhea cooperative study group
Authors: J. D. Nelson
Journal: JAMA (1976)

Single-dose antibiotic therapy was evaluated in 108 episodes of culture-confirmed, uncomplicated gonorrhea in 100 prepubertal children. There were 15 boys and 85 girls between 14 months and 14 years of age. Penicillin G procaine, 100,000 units/kg intramuscularly, was compared with amoxicillin trihydrate, 50 mg/kg orally. Probenecid, 25 mg/kg, was given simultaneously. Both drugs provided prompt bacteriological and clinical response. Multiple episodes of gonorrhea, presumably caused by reexposure, occurred in six girls. Oral and anal cultures were negative in all of 47 Costa Rican cases but were commonly positive in US children. Anal cultures yielded gonococci in 52% of girls and 25% of boys, and oral cultures were positive in 18% and 13%, respectively. In three instances, rectal cultures confirmed the diagnosis when vaginal cultures were negative. Gonorrhea should be considered in every child with vaginal or urethral discharge. Single-dose penicillin-probenecid or amoxicillin-probenecid treatment is curative. (<i>JAMA</i>236:1359-1364, 1976)
Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: A multicenter controlled trial
Authors: G Gregorio
Journal: Hepatology (1996)

The comparative efficacy of prednisolone followed by interferon alfa (IFN-α) versus IFN-α alone in enhancing the rate of antibody to hepatitis B e antigen (anti-HBe) seroconversion has not been evaluated in a large cohort of white children. To determine this, a multicenter-controlled trial was conducted in 95 hepatitis B virus (HBV)-DNA/hepatitis B e antigen (HBeAg)-positive children (median age, 9 years [range, 2-16 years]; 56 boys; 84 [89 %] white), all having inflammatory changes on liver biopsy. Patients were randomized to receive either prednisolone followed by IFN-α (n = 34); placebo followed by IFN-α (n = 30); or no treatment (n = 31). The prednisolone/placebo was given on a double-blind basis. Lymphoblastoid IFN-α was given at 5 MU/m(2) three times a week for 12 weeks. Baseline clinical, biochemical, and histological features were similar for the three groups. The majority (85 %) had a baseline aspartate aminotransferase (AST) level ≤ 100 IU/L. On follow-up between 12 and 18 months (median, 15 months) after treatment, the loss of HBeAg with anti-HBe seroconversion was more common in patients pretreated with steroids (12 of 34 [35 %]) or placebo [12 of 30 (40 %)] as against controls (4 of 31 [13 %], P< .05). Factors predictive of anti-HBe seroconversion were baseline HBV-DNA concentration of ≤ 1,000 pg/mL and a greater degree of portal tract inflammation on pretrial biopsy. Our results show that in white children treatment with IFN-α, at the dose and duration used in this study, improves the rate of anti-HBe seroconversion. Steroid priming does not potentiate the effect of IFN-α.
Anatomy of the Human Body.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE PHYSICIAN'S WRITING AND READING
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Multiple Personality
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Practical Observations on Some of the More Important Points Connected with Physical Diagnosis
Authors: C. M. Durrant
Journal: BMJ (1845)

THE AORTIC VALVES.Augculkatim.-Asuperficial bellows murmur, not extensively diffused over the thorax, accompanying the first sound; its maximum over the sternum, a little below the level of the third rib; audible in the course of the ascending aorta, carotid, and subclavian arteries.Application of the Hand.-Apurring tremor some- times perceptible, but generally rendered indistinct, in consequence of the intervention of the sternum.Ob"matiom.-Asstated on a former occasion, a bellows mnurmur, accompanying the first sound of the heart, having its greatest intensity over the base of the organ, may indicate either structural mischief, or be dependent merely upon inorganic causes.The estab- lishment of a correct diagnosis on this point becomes, in many instances, of such paramount importince, that a brief re-mention of the differential diagnosis between the two murmurs will not, in a practical point of view, be esteemed an unnecessary repetition.The distinction upon which the diagnosis is founded, rests chiefly upon the following circumstances, viz.That although both murmurs accompany the first sound of the heart, the inorganic is, limited to that
Estimates of Gestational Age
Authors: Robert J. Sokol
Journal: JAMA (1989)

<h3>To the Editor. —</h3> The article by Kramer et al<sup>1</sup>reaffirms the poor quality of estimates of gestational age afforded by dating of the last normal menstrual period (LNMP). The authors express surprise that the magnitude of the bias toward the mean of such estimates increases the further the LNMP estimate differs from the mean of the estimates. This should not come as a surprise. In fact, it can be anticipated from probabilistic considerations without collecting any data. To illustrate why bias toward the mean increasing as distance from the mean increases could be anticipated, consider the following hypothetical simplification. Suppose that all gestational ages at delivery are 39 weeks, but that the LNMP estimate has a distribution ranging from 36 to 42 weeks. Then consider a plot, like the figure on page 3307 of the article by Kramer et al, of the difference between the LNMP estimate